Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Current Assets (2019 - 2025)

Historic Current Assets for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $719.3 million.

  • Keros Therapeutics' Current Assets rose 3029.84% to $719.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $719.3 million, marking a year-over-year increase of 3029.84%. This contributed to the annual value of $588.9 million for FY2024, which is 6956.66% up from last year.
  • Latest data reveals that Keros Therapeutics reported Current Assets of $719.3 million as of Q3 2025, which was up 3029.84% from $732.8 million recorded in Q2 2025.
  • Keros Therapeutics' 5-year Current Assets high stood at $759.5 million for Q1 2025, and its period low was $222.4 million during Q2 2022.
  • Over the past 5 years, Keros Therapeutics' median Current Assets value was $334.3 million (recorded in 2023), while the average stood at $397.7 million.
  • In the last 5 years, Keros Therapeutics' Current Assets soared by 33728.45% in 2021 and then tumbled by 967.33% in 2022.
  • Keros Therapeutics' Current Assets (Quarter) stood at $251.4 million in 2021, then increased by 13.65% to $285.8 million in 2022, then rose by 21.53% to $347.3 million in 2023, then surged by 69.57% to $588.9 million in 2024, then grew by 22.15% to $719.3 million in 2025.
  • Its last three reported values are $719.3 million in Q3 2025, $732.8 million for Q2 2025, and $759.5 million during Q1 2025.